InterAx is a Swiss Biotech company spinoff from the ETH Zürich and Paul Scherrer Institute.
InterAx assists drug candidate design and selection with its unique and novel systems biology platform. This technology allows for the integration of both, experimental and computational pharmacology, and is able to predict in vivo effects of drug candidates by analyzing complex experimental in vitro data sets. Currently, the InterAx technology is applicable to all drug discovery programs on G protein-coupled receptors (GPCRs).
Meet us at the upcoming events and conferences
June 2019 - RSC Anglo-Nordic Medicinal Chemistry symposium (DK)
October 2019 - GDR3545 - GPCR International Meeting (FR)
November 2019 - BIO Europe (DE)
December 2019 - The British Pharmacological Society - Pharmacology 2019 (UK)